Rational Vaccines Inc
Rational Vaccines is an infectious disease company focused on developing vaccines and therapeutics to combat herpes simplex virus (HSV-1 and HSV-2) infections. They aim to revolutionize the treatment, prevention, and diagnosis of herpes and herpes-related diseases worldwide through proprietary technology and rationally engineered live attenuated viral vaccines. The company is also involved in COVID-19 testing and vaccine development, leveraging their expertise in viral immunotherapeutics.
Industries
Nr. of Employees
small (1-50)
Rational Vaccines Inc
Woburn, Massachusetts, United States, North America
Products
Therapeutic live-attenuated HSV-2 vaccine candidate (lead)
A replication-competent, rationally attenuated herpesvirus vaccine candidate designed to modulate immune control of recurrent HSV infection via targeted mutations that reduce immune evasion; progressed through preclinical development with reported early clinical safety follow-up.
Prophylactic live-attenuated HSV vaccine candidates (HSV-1 and HSV-2)
Preclinical-stage replication-competent vaccine candidates intended for prevention of HSV-1 and HSV-2 infection developed using rational attenuation principles.
Multi-antigen IgG serological assay for SARS-CoV-2
A serological test format that assesses antibodies to multiple viral proteins and includes methods to subtract cross-reactive antibodies to improve specificity, adapted from an assay architecture originally developed for herpesvirus serology.
HSV-based viral vector platform (adaptation project)
Platform work to convert an attenuated herpesvirus immunotherapeutic into a viral vector format for delivery of heterologous antigens for other vaccine applications.
Therapeutic live-attenuated HSV-2 vaccine candidate (lead)
A replication-competent, rationally attenuated herpesvirus vaccine candidate designed to modulate immune control of recurrent HSV infection via targeted mutations that reduce immune evasion; progressed through preclinical development with reported early clinical safety follow-up.
Prophylactic live-attenuated HSV vaccine candidates (HSV-1 and HSV-2)
Preclinical-stage replication-competent vaccine candidates intended for prevention of HSV-1 and HSV-2 infection developed using rational attenuation principles.
Multi-antigen IgG serological assay for SARS-CoV-2
A serological test format that assesses antibodies to multiple viral proteins and includes methods to subtract cross-reactive antibodies to improve specificity, adapted from an assay architecture originally developed for herpesvirus serology.
HSV-based viral vector platform (adaptation project)
Platform work to convert an attenuated herpesvirus immunotherapeutic into a viral vector format for delivery of heterologous antigens for other vaccine applications.
Expertise Areas
- Live-attenuated vaccine development
- Viral vector engineering
- Preclinical animal model evaluation
- Serological assay development
Key Technologies
- Live-attenuated viral vaccine platforms
- ICP0-targeted genetic attenuation
- HSV-based viral vectors
- Multi-antigen IgG serology